Scinai Immunotherapeutics Ltd. cash flow statement SCNI

In Q1 of fiscal 2023, the quarter ended Mar 31, 2023, Scinai Immunotherapeutics Ltd. used $3.1 million of cash from operations. It spent $6,000 on capital expenditures. Free cash flow was negative, at -$3.1 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
Q1 FY2023
Mar 31, 2023
Operating
Depreciation and amortization
0
Stock-based compensation
0
Operating cash flow
-3
Investing
Capital expenditures
0
Investing cash flow
-0
Change in cash
Effect of exchange rate
-0
Net change in cash
-3
Free cash flow
-3
Per share
Free cash flow per share
-0.00
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
SCNI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Jerusalem, Israel
SEC filer status
Non-accelerated filer
SEC CIK
1611747
Former names
BiondVax Pharmaceuticals Ltd. (until Aug 28, 2023)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.